UBS Group Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its target price lowered by investment analysts at UBS Group from $135.00 to $125.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the healthcare product maker’s stock. UBS Group’s price objective would indicate a potential upside of 16.30% from the company’s previous close.

ABT has been the topic of several other reports. Leerink Partners reduced their target price on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Bank of America lowered their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Evercore cut their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Barclays decreased their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Finally, Benchmark lowered their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.17.

Abbott Laboratories Stock Up 2.9%

NYSE ABT traded up $2.99 on Tuesday, hitting $107.48. The stock had a trading volume of 7,884,222 shares, compared to its average volume of 12,332,799. The business’s fifty day moving average price is $91.95 and its 200 day moving average price is $100.99. The stock has a market cap of $187.21 billion, a price-to-earnings ratio of 34.77, a price-to-earnings-growth ratio of 2.00 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Institutional Investors Weigh In On Abbott Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of the company. Sunpointe LLC boosted its position in Abbott Laboratories by 3.6% in the second quarter. Sunpointe LLC now owns 3,658 shares of the healthcare product maker’s stock valued at $332,000 after buying an additional 128 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA increased its holdings in Abbott Laboratories by 6.9% in the 2nd quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 4,204 shares of the healthcare product maker’s stock worth $381,000 after buying an additional 272 shares during the period. Bogart Wealth LLC raised its position in Abbott Laboratories by 132.8% during the 2nd quarter. Bogart Wealth LLC now owns 1,951 shares of the healthcare product maker’s stock worth $177,000 after buying an additional 1,113 shares during the last quarter. TCV Trust & Wealth Management Inc. lifted its stake in Abbott Laboratories by 2.6% during the 2nd quarter. TCV Trust & Wealth Management Inc. now owns 125,717 shares of the healthcare product maker’s stock valued at $11,408,000 after acquiring an additional 3,199 shares during the period. Finally, Brookmont Capital Management boosted its holdings in shares of Abbott Laboratories by 0.4% in the 2nd quarter. Brookmont Capital Management now owns 37,463 shares of the healthcare product maker’s stock valued at $3,399,000 after acquiring an additional 167 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Raised profit outlook and quarterly beat: Abbott exceeded second-quarter earnings expectations, with revenue rising 13% year over year, and increased its full-year 2026 adjusted EPS guidance to $5.45-$5.60. Strong demand for cancer diagnostics and medical devices helped offset concerns about procedure volumes. Abbott Raised Its Profit Forecast
• Positive Sentiment: Colorectal cancer screening opportunity: Abbott secured exclusive U.S. commercialization rights for Freenome’s FDA-approved SimpleScreen blood-based colorectal cancer test. The product could broaden screening access, supported by Medicare coverage and clinical guidance, while expanding Abbott’s diagnostics portfolio. FDA Approves Freenome’s SimpleScreen CRC Test
• Positive Sentiment: Multiple innovation-led growth paths: New products, acquisitions and investments in diabetes care, oncology diagnostics and cardiovascular devices give Abbott several potential sources of longer-term growth. Abbott Rides Key Innovation Trends
• Neutral Sentiment: New cardiac-monitoring technology: Implicity received FDA clearance for an AI-powered analyzer that supports implantable cardiac monitors and may reduce false-positive alerts. The development supports the broader cardiac-care ecosystem, although the direct financial benefit to Abbott is not yet clear. Implicity’s Next-Generation ILR ECG Analyzer
• Negative Sentiment: Valuation and risk concerns: Analysts note that much of the improved earnings outlook may already be reflected in ABT’s valuation, limiting near-term upside. Earlier coverage also highlighted litigation concerns and uncertainty around medical-procedure volumes, which could weigh on sentiment despite the stronger forecast. Is Abbott Stock Attractive After Its Earnings and Guidance Update?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.